Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
/in Acute Leukemia, Dendritic Cells, International PublicationsDendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
/in Dendritic Cells, International Publications, NSCLCPredicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
/in Dendritic Cells, International Publications, Pancreatic CancerThe effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
/in Cervical Cancer, Hyperthermia, International PublicationsEditorial: Vitamin C in Cancer and Infectious Diseases: Physiological, Biochemical and Therapeutic Interventions
/in International Publications, MicronutrientsSafety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsAssessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
/in Breast Cancer, Dendritic Cells, International PublicationsModulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
/in Colorectal Cancer, Hyperthermia, International PublicationsPhase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer